Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
J Ethnopharmacol ; 267: 113463, 2021 Mar 01.
Article in English | MEDLINE | ID: mdl-33049347

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Leeches (pinyin name Shui Zhi; Latin scientific name Hirudo; Hirudinea; Hirudinidae) and centipedes (pinyin name Wu Gong; Latin scientific name Scolopendridae; Chilopoda; Scolopendridae) are traditional Chinese medicines, and they belong to the family entomology. A combination of leech and centipede is used as an effective medicine to promote blood circulation and remove blood stasis in traditional Chinese medicine, and "leech-centipede" medicine has been used in many prescriptions to treat diabetic vascular disease, including diabetic erectile dysfunction (DIED). However, its specific mechanism remains unclear and requires in-depth study. AIM OF THE STUDY: This study aimed to investigate the mechanism of "leech-centipede" medicine to improve erectile dysfunction-associated diabetes by detecting PKC pathway-related molecules. MATERIALS AND METHODS: The active ingredients of "leech-centipede" medicine were identified using high performance liquid chromatography (HPLC). Fifty male SPF rats were injected with streptozotocin to induce the DM model. Eight weeks later, the DMED model was validated with apomorphine. The DIED rats were divided into five groups-T,P,DD,DZ, and DG-and were separately treated with tadalafil, pathway inhibitor LY333531 and low-, medium-, and high-dose "leech-centipede" medicine for 8 weeks. After treatment, the blood glucose level was measured, erectile function with apomorphine was assessed, the LOX-1, sE-selectin, sICAM-1, SOD, and MDA in serum was evaluated by enzyme-linked immunosorbent assay, and flow cytometry was performed. After the collection of penile tissue, the related protein and mRNA expression was assessed by Western blotting and PCR, and the tissue and ultrastructure were analysed by HE staining, immunohistochemistry and scanning electron microscopy. RESULTS: After treatment, the erectile function of rats was significantly improved in the T,P,DD,DZ, and DG groups compared with that in the model group. Thus, "leech-centipede" medicine can significantly reduce the levels of LOX-1, sE-selectin, sICAM-1, EMPs and CD62P to protect vascular endothelial function and anti-platelet activation, improving DIED rat erectile function. Additionally, "leech-centipede" medicine can increase SOD expression and decrease MDA expression, reducing the possibility of oxidative stress injury in DIED rats and improving the antioxidant capacity. Moreover, "leech-centipede" therapy can dramatically reduce the protein and mRNA expression of DAG, PKCß, NF-κB, and ICAM-1, improve vascular endothelial injury in DIED rats and inhibit abnormal platelet activation. CONCLUSION: "leech-centipede" medicine can improve erectile dysfunction by inhibiting the expression of PKC pathway-related molecules in DIED rats and protects endothelial function and anti-platelet activation.


Subject(s)
Chilopoda , Cyclic AMP-Dependent Protein Kinase Catalytic Subunits/metabolism , Diabetes Complications/drug therapy , Leeches , Penile Erection/drug effects , Penis/drug effects , Tissue Extracts/pharmacology , Animals , Biomarkers/metabolism , Cyclic AMP-Dependent Protein Kinase Catalytic Subunits/genetics , Diabetes Complications/enzymology , Diabetes Complications/etiology , Diabetes Complications/physiopathology , Diabetes Mellitus, Experimental/chemically induced , Diglycerides/metabolism , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Male , Medicine, Chinese Traditional , NF-kappa B/genetics , NF-kappa B/metabolism , Oxidative Stress/drug effects , Penis/enzymology , Penis/physiopathology , Platelet Activation/drug effects , Rats, Sprague-Dawley , Recovery of Function , Signal Transduction , Streptozocin
2.
J Diabetes Res ; 2020: 8982676, 2020.
Article in English | MEDLINE | ID: mdl-32879893

ABSTRACT

BACKGROUND: Increased activity of aldose reductase (AR) is one of the mechanisms involved in the development of diabetic complications. Inhibiting AR can be a target to prevent diabetes complications. This study is aimed at evaluating the effect of cyclohexane (CH) and ethanol extracts (ET) of walnut leaves on AR activity in the lens and testis of diabetic rats. METHODS: Fifty-six male rats classified into seven groups as control and treatment groups and treated for 30 days. The treatment groups were treated with different concentrations of ET and CH. The diabetic control (DC) group was exposed to streptozotocin. AR activity was measured in the lens and testis. The expression of AR in the testis was evaluated by the immunohistochemistry method. RESULTS: Both extracts significantly reduced the AR activity (ng/mg of tissue protein) in the testis (0.034 ± 0.004, 0.038 ± 0.010, and 0.040 ± 0.007 in the treatment groups vs. 0.075 ± 0.007 in the DC group) and lens (1.66 ± 0.09, 2.70 ± 0.47, and 1.77 ± 0.20 in the treatment groups vs. 6.29 ± 0.48 in the DC group) of the treatment group compared to those of the DC group (P < 0.05). AR expression in the testes of the treatment groups was decreased compared with that of the DC group (P < 0.0001). CONCLUSION: Walnut leaf extracts can reduce the activity and localization of AR in the testes and its activity in the lens of diabetic rats.


Subject(s)
Aldehyde Reductase/metabolism , Diabetes Complications/prevention & control , Diabetes Mellitus, Experimental/enzymology , Hypoglycemic Agents/pharmacology , Lens, Crystalline/drug effects , Plant Extracts/pharmacology , Animals , Diabetes Complications/enzymology , Hypoglycemic Agents/therapeutic use , Juglans , Lens, Crystalline/enzymology , Male , Plant Extracts/therapeutic use , Plant Leaves , Rats , Rats, Sprague-Dawley , Testis/drug effects , Testis/enzymology
3.
J Food Biochem ; 43(3): e12758, 2019 03.
Article in English | MEDLINE | ID: mdl-31353546

ABSTRACT

The effects of aqueous-ethanol extract of Horse chestnut (HCE) on MMP-1 and MMP-9 expressions during cutaneous wound healing in diabetic rats were investigated in this study. The expressions of MMP-1 and MMP-9, wound closure, myeloperoxidase (MPO) activity, hydroxyproline, and malondialdehyde (MDA) levels in wound tissue were measured. Quercetin glucuronide in HCE was identified as main compound using a LC-MS/MS. The hydroxyproline level was significantly increased in the treated group versus control after the 3rd and 7th days (p < 0.05). The MDA level and MPO activity were significantly lower in the treatment group (p < 0.05). MMP-1 gene expression level in treated rats was increased in the 7th day while it was reduced in 14th day. MMP-9 gene expression level in treated rats was decreased in 7th, and 14th days compared to control (p < 0.05). These results show that HCE accelerated the cutaneous wound-healing process in diabetic rats via MMP-1 and MMP-9 regulation. PRACTICAL APPLICATIONS: The main function of MMPs is to degrade and deposite the various components of the extracellular matrix. Also, they participate physiological processes such as inflammation, angiogenesis, and tissue remodeling. Horse chestnut seeds (HC) are known to be rich in saponins and flavonoids. HC are used for the treatment of abdominal pain, stomach ache, cold, hemorrhoids, arterial stiffness, rheumatism, oedema, diarrhea, chronic venous insufficiency and also as an antihemorrhagic and antipyretic in traditional medicine. It has been shown that HC has anti-inflammatory, antioedema, vessel protective, and free radical scavenging properties. This study indicates that HCE could be an effective agent for wound healing in diabetic wound model via its ability to suppress the MMP-9 gene expression and regulates MMP-1 gene expression besides its antioxidative, anti-inflammatory effects.


Subject(s)
Aesculus/chemistry , Diabetes Complications/drug therapy , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 9/metabolism , Plant Extracts/administration & dosage , Wounds and Injuries/drug therapy , Animals , Diabetes Complications/enzymology , Diabetes Complications/genetics , Diabetes Complications/physiopathology , Female , Humans , Male , Matrix Metalloproteinase 1/genetics , Matrix Metalloproteinase 9/genetics , Rats , Rats, Wistar , Seeds/chemistry , Wound Healing/drug effects , Wounds and Injuries/enzymology , Wounds and Injuries/genetics , Wounds and Injuries/physiopathology
4.
Expert Opin Ther Pat ; 29(3): 199-213, 2019 03.
Article in English | MEDLINE | ID: mdl-30760060

ABSTRACT

INTRODUCTION: Aldose reductase (ALR2) is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Accordingly, it represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it. AREAS COVERED: This literature survey summarizes patents and patent applications published over the last 5 years and filed for natural, semi-synthetic and synthetic ALR2 inhibitors. Compounds described have been discussed and analyzed from both chemical and functional angles. EXPERT OPINION: Several ALR2 inhibitors with a promising pre-clinical ability to address diabetic complications and inflammatory diseases are being developed during the observed timeframe. Natural compounds and plant extracts are the prevalent ones, thus confirming the use of phytopharmaceuticals as an increasingly pursued therapeutic trend also in the ALR2 inhibitors field. Intriguing hints may be taken from synthetic derivatives, the most significant ones being represented by the differential inhibitors ARDIs. Differently from classical ARIs, these compounds should fire up the therapeutic efficacy of the class while minimizing its side effects, thus overcoming the existing limits of this kind of inhibitors.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Drug Design , Enzyme Inhibitors/pharmacology , Aldehyde Reductase/metabolism , Animals , Diabetes Complications/drug therapy , Diabetes Complications/enzymology , Enzyme Inhibitors/adverse effects , Humans , Inflammation/drug therapy , Inflammation/enzymology , Patents as Topic
5.
Prog Lipid Res ; 73: 28-45, 2019 01.
Article in English | MEDLINE | ID: mdl-30472260

ABSTRACT

12/15-lipoxygenase (12/15-LOX) is an enzyme, which oxidizes polyunsaturated fatty acids, particularly omega-6 and -3 fatty acids, to generate a number of bioactive lipid metabolites. A large number of studies have revealed the importance of 12/15-LOX role in oxidative and inflammatory responses. The in vitro studies have demonstrated the ability of 12/15-LOX metabolites in the expression of various genes and production of cytokine related to inflammation and resolution of inflammation. The studies with the use of knockout and transgenic animals for 12/15-LOX have further shown its involvement in the pathogenesis of a variety of human diseases, including cardiovascular, renal, neurological and metabolic disorders. This review summarizes our current knowledge on the role of 12/15-LOX in inflammation and various human diseases.


Subject(s)
Arachidonate 12-Lipoxygenase/metabolism , Arachidonate 15-Lipoxygenase/metabolism , Inflammation/enzymology , Animals , Animals, Genetically Modified , Arachidonate 12-Lipoxygenase/genetics , Arachidonate 15-Lipoxygenase/genetics , Diabetes Complications/enzymology , Diabetes Complications/pathology , Disease Models, Animal , Fatty Acids, Omega-3/metabolism , Fatty Acids, Omega-6/metabolism , Humans , Inflammation/pathology , Nervous System Diseases/enzymology , Nervous System Diseases/pathology , Obesity/enzymology , Obesity/pathology , Vascular Diseases/enzymology , Vascular Diseases/pathology
6.
Biomed Pharmacother ; 83: 221-228, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27372406

ABSTRACT

PURPOSE: Tephrosia purpurea (T. purpurea) has been reported to prevent cataract formation in senile cataract model as well as proven effective in STZ induced type 1 diabetes. Aldose reductase (AR) is a key enzyme in the intracellular polyol pathway responsible for the development of diabetic cataract. OBJECTIVE: To investigate the effects of T. purpurea in the light of inhibition of aldose reductase enzyme in polyol pathway. METHODS: We studied the effects of alcoholic extract and flavonoid fraction of T. purpurea in streptozotocin (STZ, 45mg/kg, i.v.)-induced type I diabetic cataract in rats. The animals were divided into five groups as control, control treated with alcoholic and flavonoid fraction, diabetic control and diabetic treated with alcoholic and flavonoid fraction. In-vitro aldose reductase inhibitory activity was also evaluated. Further, molecular docking study was performed with crystal structure of aldose reductase and its known chemical constituents of the plant. RESULTS: The IC50 value of alcoholic extract for aldose reductase inhibition was found to be 209.13µg/ml, and that of flavonoid fraction was found to be 46.73µg/ml. Administration of STZ produced significantly abnormal levels of serum glucose, serum insulin, soluble protein and antioxidants in the lens homogenate. Treatment with alcoholic extract and flavonoid fraction of T. purpurea were able to normalize these levels. Some of the active constituents of T. purpurea showed significant interactions with aldose reductase enzyme in molecular docking studies. CONCLUSIONS: Our data suggested that both the extracts might be helpful in delaying the development of diabetic cataract due to the presence of rutin and quercetin. This beneficial effect may be due to its significant inhibition of aldose reductase enzyme and anti-oxidant activity.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Cataract/drug therapy , Cataract/enzymology , Diabetes Complications/drug therapy , Enzyme Inhibitors/therapeutic use , Plant Extracts/therapeutic use , Protective Agents/therapeutic use , Tephrosia/chemistry , Aldehyde Reductase/metabolism , Animals , Antioxidants/metabolism , Binding Sites , Biphenyl Compounds/chemistry , Blood Glucose/metabolism , Cataract/blood , Diabetes Complications/blood , Diabetes Complications/enzymology , Enzyme Inhibitors/pharmacology , Female , Free Radical Scavengers/pharmacology , Insulin/blood , Lens, Crystalline/drug effects , Lens, Crystalline/metabolism , Lens, Crystalline/pathology , Male , Molecular Docking Simulation , Phytochemicals/analysis , Picrates/chemistry , Plant Extracts/pharmacology , Protective Agents/pharmacology , Rats, Sprague-Dawley , Solubility
7.
Pharm Biol ; 54(8): 1326-33, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26439719

ABSTRACT

CONTEXT: Zygophyllum album L. (Zygophyllaceae), commonly known as Bougriba, is widely used to treat diabetes, digestive tract spasm, and hypertension in folk medicine, in Tunisia. OBJECTIVE: This study investigates the antidiabetic, antidiarrheal, and antihypertensive activities of the leaves of the essential oil from Zygophyllum album (OZA) in alloxan-induced diabetic rats. MATERIALS AND METHODS: The oil was obtained by hydrodistillation and analyzed by GC-MS. Males rats were divided into four groups: control, diabetic-untreated group, diabetic-treated group with acarbose (10 mg/kg), and diabetic-treated rats with OZA (200 mg/kg) for 30 d. RESULTS: At the end of the experimental period, the OZA significantly decreased the activity of α-amylase in pancreas and serum of the diabetic rats by 43% and 38%, respectively, which led to reduce the serum glucose level by 60% and lower of glycated hemoglobin (HbA1c) rate by 17% as compared with untreated diabetic animals. Moreover, the OZA treatment attenuated symptoms of diarrhea, improved lipid disorders, and hypertension through inhibiting the pancreatic lipase and angiotensin-converting enzyme (ACE) activities by 47% and 25%, respectively, in serum of diabetic rats. CONCLUSION: OZA showed a good effect in the management of diabetes mellitus and exerted preventive action from related hypertension.


Subject(s)
Alloxan , Antidiarrheals/pharmacology , Antihypertensive Agents/pharmacology , Diabetes Complications/prevention & control , Diabetes Mellitus, Experimental/drug therapy , Enzyme Inhibitors/pharmacology , Hypoglycemic Agents/pharmacology , Oils, Volatile/pharmacology , Plant Oils/pharmacology , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Antidiarrheals/isolation & purification , Antihypertensive Agents/isolation & purification , Blood Glucose/drug effects , Blood Glucose/metabolism , Blood Pressure/drug effects , Chromatography, Liquid , Diabetes Complications/blood , Diabetes Complications/enzymology , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/enzymology , Digestion/drug effects , Enzyme Inhibitors/isolation & purification , Gas Chromatography-Mass Spectrometry , Glycated Hemoglobin/metabolism , Hypoglycemic Agents/isolation & purification , Male , Oils, Volatile/isolation & purification , Pancreas/drug effects , Pancreas/enzymology , Phytotherapy , Plant Leaves , Plant Oils/isolation & purification , Plants, Medicinal , Rats, Wistar , Time Factors , Zygophyllum/chemistry , alpha-Amylases/antagonists & inhibitors , alpha-Amylases/blood
8.
BMC Complement Altern Med ; 14: 435, 2014 Nov 06.
Article in English | MEDLINE | ID: mdl-25374323

ABSTRACT

BACKGROUND: Diabetes complications include various symptoms such as diabetic neuropathy and cognitive disorders. Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway and is one of the causal factors of diabetes complications. In this study, the bioactivities of eight selected Kampo formulations that are currently in clinical use for diabetes complications were assessed using human AR (hAR) inhibitory activity as the primary parameter to explore the possibilities of novel clinical applications of these formulations in the treatment of diabetes complications. METHODS: The hAR inhibitory activities of four Kampo formulations that are clinically used for diabetic neuropathy, four Kampo formulations that are used for cognitive disorders, and a total of 21 component crude drugs were measured. Furthermore, the hAR inhibitory activity of Glycyrrhizae Radix preparata was measured to determine the effect of frying, which is one of the specific processing of Glycyrrhizae Radix. hAR inhibitory activity was determined by measuring the rate of decline in the absorbance of NAPH at 340 nm using 0.5 mM NADPH, 10 mM D,L-glyceraldehyde, and 3.6 mU/mL hAR in phosphate buffer solution (0.2 M, pH 6.2). RESULTS: All of the Kampo formulations exhibited significant hAR inhibitory activity; Chotosan exhibited particularly strong activity. Among the 21 crude drugs tested, adequate inhibitory activities were found for the following, in descending order of activity: Glycyrrhizae Radix > Paeoniae Radix > Chrysanthemi Flos > Cinnamomi Cortex > Phellodendri Cortex > Uncariae Uncis cum Ramulus > Bupleuri Radix. Glycyrrhizae Radix preparata exhibited an inhibitory activity that was nearly identical to that of Glycyrrhizae Radix. CONCLUSIONS: Despite their seemingly different treatment objectives, all of the Kampo formulations that are clinically used for diabetes complications demonstrated significant hAR inhibitory activity. This activity might underlie the characteristic multi-target effects of Kampo formulations. Although the overall effect of a Kampo formulation is certainly difficult to evaluate based on specific herbal medications or components, the approach as taken in this study might nonetheless contribute to further advancement in the development of new drugs via the review of proper usage and re-examination of the chemical compounds from a new perspective.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Diabetes Complications/enzymology , Enzyme Inhibitors/pharmacology , Medicine, Kampo , Plant Extracts/pharmacology , Plants, Medicinal/chemistry , Aldehyde Reductase/metabolism , Diabetes Complications/drug therapy , Humans
9.
BMC Complement Altern Med ; 14: 422, 2014 Oct 28.
Article in English | MEDLINE | ID: mdl-25351676

ABSTRACT

BACKGROUND: Castanea mollissima Blume (Chinese chestnut), as a food product is known for its various nutrients and functional values to the human health. The present study was carried out to analyze the anti-diabetic complications and anti-cancer activities of the bioactive compounds present in C. mollissima. METHODS: The kernels (CK), shells (CS) and involucres (CI) parts of C. Blume were extracted with 90% alcohol. The water suspension of these dried alcohol extracts were extracted using EtOAc and n-BuOH successively. The n-BuOH fraction of CI (CI-B) was isolated by silica gel column, Sephadex LH 20 column and preparative HPLC. The isolated compounds were identified by 1H-NMR, 13C-NMR, HMBC, HMQC and ESI-Q-TOF MS, All the fractions and compounds isolated were evaluated on human recombinant aldose reductase (HR-AR) assay, advanced glycation end products (AGEs) formation assay and human COLO 320 DM colon cancer cells inhibitory assay. RESULTS: CI-B was found to show a significant inhibitory effect in above biological screenings. Six flavonoids and three polyphenolic acids were obtained from CI-B. They were identified as kaempferol (1), kaempferol-3-O-[6''-O-(E)-p-coumaroyl]-ß-D-glucopyranoside (2), kaempferol-3-O-[6''-O-(E)-p-coumaroyl]-ß-D-galactopyranoside (3), kaempferol-3-O-[2''-O-(E)-p-coumaroyl]-ß-D-glucopyranoside (4), kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-ß-D-glucopyranoside (5) and kaempferol-3-O-[2", 6"-di-O-(E)-p-coumaroyl]-ß-D-galactopyranoside (6), casuariin (7), casuarinin (8) and castalagin (9). Compounds 2-9 were found to show higher activity than quercetin (positive control) in the AR assay. Compounds 3-6, 8, and 9 showed stronger inhibitory effects than amino guanidine (positive control) on AGEs production. Compounds 4-6, 7, and 8 showed much higher cytotoxic activity than 5-fluorouracil (positive control) against the human COLO 320 DM colon cancer cells. CONCLUSIONS: Our results suggest that flavonoids and polyphenolic acids possesses anti-diabetes complications and anti-cancer properties, and they were presumed to be the bioactive components of Castanea mollissima Blume.


Subject(s)
Antineoplastic Agents, Phytogenic/chemistry , Fagaceae/chemistry , Hypoglycemic Agents/chemistry , Plant Extracts/chemistry , Aldehyde Reductase/antagonists & inhibitors , Aldehyde Reductase/metabolism , Antineoplastic Agents, Phytogenic/pharmacology , Chromatography, High Pressure Liquid , Diabetes Complications/drug therapy , Diabetes Complications/enzymology , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Flavonoids/chemistry , Flavonoids/pharmacology , Fluorouracil/chemistry , Fluorouracil/pharmacology , Humans , Hypoglycemic Agents/pharmacology , Molecular Structure , Neoplasms/drug therapy , Neoplasms/enzymology , Plant Extracts/pharmacology
10.
BMC Complement Altern Med ; 14: 291, 2014 Aug 08.
Article in English | MEDLINE | ID: mdl-25104050

ABSTRACT

BACKGROUND: We hypothesized that C. borivilianum root, known to improve male reproductive performance, prevents impairment in characteristics, morphology and elevation of oxidative stress in sperm of diabetics. We therefore investigated the effect of aqueous root extract of C. borivilianum on these parameters in diabetic rat model. METHODS: C. borivilianum root aqueous extract (250 and 500 mg/kg/day) or glibenclamide (600 µg/kg/day) were administered to streptozotocin (STZ)-induced diabetic male rats for 28 consecutive days. At the end of treatment, animals were sacrificed and sperm were collected. Sperm count and percentages of forward motility, viability, hypoosmotic swelling (HOS) tail-coiled and abnormal sperm were evaluated. Sperm lipid peroxidation product (LPO), hydrogen peroxide (H2O2) and nitric oxide (NO) levels, total antioxidant capacity (TAC), activity levels of endogenous antioxidant enzymes (superoxide dismutase-SOD, catalase-CAT and glutathione peroxidase-GPx), epididymal sperm density, serum fasting blood glucose (FBG) and HbA1c levels were measured. The expression of sperm caspase-3 was assessed. Meanwhile, in-vitro free radical scavenging activity of C. borivilianum root extract was determined and the root extract was analyzed for the presence of bioactive compounds by FTIR spectroscopy. RESULTS: C. borivilianum root aqueous extract prevents the decrease in sperm count, percentages of forward motility, viability, HOS and the increase in abnormal sperm percentage and caspase-3 level in diabetic rats. Sperm LPO, H2O2 and NO levels, FBG and HbA1c were lower while TAC, SOD, CAT, GPx and epididymal sperm density were higher in diabetic rats receiving C. borivilianum root extract treatment. C. borivilianum root exhibited strong in-vitro free radical scavenging activity which may be due to the phenolic compound. CONCLUSIONS: C. borivilianum root extract prevents impairment in sperm characteristics and morphology via preventing elevation of oxidative stress, apoptosis and free radicals levels of the sperm in diabetes. These effects may be achieved through maintaining sperm antioxidant level which could be related to free radical scavenging activity of the root extract by phenolic compounds. These effects could also be due to ability of the extract to maintain near normal serum FBG and HBA1c levels in diabetes.


Subject(s)
Diabetes Complications/prevention & control , Infertility, Male/prevention & control , Liliaceae/chemistry , Oxidative Stress/drug effects , Plant Extracts/administration & dosage , Spermatozoa/drug effects , Animals , Antioxidants/administration & dosage , Blood Glucose/metabolism , Caspase 3/metabolism , Catalase/metabolism , Diabetes Complications/enzymology , Diabetes Complications/etiology , Diabetes Complications/metabolism , Diabetes Mellitus/chemically induced , Diabetes Mellitus/metabolism , Glutathione Peroxidase/metabolism , Humans , Hydrogen Peroxide/metabolism , Infertility, Male/enzymology , Infertility, Male/etiology , Infertility, Male/metabolism , Lipid Peroxidation/drug effects , Male , Plant Roots/chemistry , Rats , Rats, Wistar , Sperm Motility/drug effects , Spermatozoa/cytology , Spermatozoa/enzymology , Spermatozoa/metabolism , Streptozocin , Superoxide Dismutase/metabolism
11.
Lab Invest ; 94(4): 382-93, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24614196

ABSTRACT

Endothelial dysfunction, characterized by impairment of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) bioavailability, has been implicated in diabetic cardiovascular pathogenesis. In this study, low-molecular-weight fucoidan (LMWF), which has multiple biological activities including anti-inflammatory and anti-oxidative properties, was investigated for its protective effect against endothelial dysfunction in Goto-Kakizaki type 2 diabetic rats. LMWF (50, 100, or 200 mg/kg/day) or probucol (100 mg/kg/day) were given to diabetic rats for 12 weeks. Basal blood pressure, acetylcholine- or flow-mediated relaxation of mesenteric and paw arteries, endothelium-dependent dilation of aorta, eNOS phosphorylation, and NO production were measured using laser Doppler flowmetry, force myograph, hematoxylin and eosin staining, western blot analysis, and an NO assay. We found that LMWF robustly ameliorated the basal hypertension and impairment of endothelium-dependent relaxation in the aorta, as well as mesenteric and paw arteries in diabetic rats. In addition, the reduction in eNOS phosphorylation at Ser1177, eNOS expression, and NO production because of diabetes were partially reversed by LMWF treatment. However, probucol, a lipid-modifying drug with antioxidant properties, displayed only mild effects. Moreover, LMWF induced, in a dose-dependent manner, endothelium-dependent vasodilation and eNOS phosphorylation at Ser1177 in normal aorta, and also promoted Ser1177 phosphorylation and NO synthesis in primary cultured vasoendothelial cells. Thus, these data demonstrate for the first time that fucoidan protects vasoendothelial function and reduces basal blood pressure in type 2 diabetes rats via, at least in part, preservation of eNOS function. Fucoidan is therefore a potential candidate drug for protection of endothelium in diabetic cardiovascular complications.


Subject(s)
Antithrombins/therapeutic use , Diabetes Complications/prevention & control , Endothelium, Vascular/drug effects , Hypertension/prevention & control , Polysaccharides/therapeutic use , Animals , Antithrombins/pharmacology , Aorta/drug effects , Diabetes Complications/enzymology , Disease Models, Animal , Drug Evaluation, Preclinical , Endothelial Cells/drug effects , Endothelial Cells/metabolism , Hypertension/etiology , Male , Mesentery/drug effects , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/metabolism , Polysaccharides/pharmacology , Rats , Rats, Wistar , Vasodilation/drug effects
12.
Int J Food Sci Nutr ; 64(8): 974-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23862759

ABSTRACT

This study evaluated the antioxidant and androgenic properties of ginger roots on the reproductive function of male diabetic rats. Animals were divided into three groups; the control (Control), diabetic (Diab) and diabetic fed with dietary ginger for 30 d (Diab + Z). Thereafter, blood samples were collected and reproductive organs (testis, epididymis, prostate and seminal vesicle) were removed for determination of sperm parameters, malondialdehyde (MDA) level, glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase (CAT), lactate dehydrogenase (LDH), alkaline phosphatase (ALP) and aspartate and lactate aminotransferase (AST and ALT) activities. Dietary ginger decreased blood glucose and MDA level, increased reproductive organ weights and testosterone level, improved semen quantity and motility, and ameliorated the SOD, CAT and GPx activities as well as testis AST, ALT, LDH and ALP activities. Intake of ginger roots improves the antioxidant and androgenic reproductive function of male diabetic rats in addition to its antidiabetic property.


Subject(s)
Androgens/pharmacology , Antioxidants/pharmacology , Diabetes Complications/prevention & control , Diet , Infertility/prevention & control , Oxidative Stress/drug effects , Zingiber officinale , Androgens/therapeutic use , Animals , Antioxidants/metabolism , Antioxidants/therapeutic use , Catalase/metabolism , Diabetes Complications/enzymology , Diabetes Complications/metabolism , Glutathione Peroxidase/metabolism , Infertility/metabolism , Lipid Peroxidation/drug effects , Male , Malondialdehyde/metabolism , Phytotherapy , Plant Preparations/pharmacology , Plant Preparations/therapeutic use , Rats , Rats, Wistar , Rhizome , Semen/drug effects , Superoxide Dismutase/metabolism , Testis/metabolism , Testosterone/blood
13.
Biomed Res Int ; 2013: 727143, 2013.
Article in English | MEDLINE | ID: mdl-23586057

ABSTRACT

Aldose reductase (AR) inhibitors have a considerable therapeutic potential against diabetes complications and do not increase the risk of hypoglycemia. Through bioassay-guided fractionation of an EtOH extract of the kernel from purple corn (Zea mays L.), 7 nonanthocyanin phenolic compounds (compound 1-7) and 5 anthocyanins (compound 8-12) were isolated. These compounds were investigated by rat lens aldose reductase (RLAR) inhibitory assays. Kinetic analyses of recombinant human aldose reductase (rhAR) were performed, and intracellular galactitol levels were measured. Hirsutrin, one of 12 isolated compounds, showed the most potent RLAR inhibitory activity (IC(50), 4.78 µ M). In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate concentration, hirsutrin showed competitive inhibition against rhAR. Furthermore, hirsutrin inhibited galactitol formation in rat lens and erythrocytes sample incubated with a high concentration of galactose; this finding indicates that hirsutrin may effectively prevent osmotic stress in hyperglycemia. Therefore, hirsutrin derived from Zea mays L. may be a potential therapeutic agent against diabetes complications.


Subject(s)
Aldehyde Reductase/metabolism , Diabetes Complications/enzymology , Hypoglycemia/enzymology , Hypoglycemic Agents/administration & dosage , Plant Extracts/administration & dosage , Aldehyde Reductase/antagonists & inhibitors , Animals , Anthocyanins/administration & dosage , Anthocyanins/chemistry , Diabetes Complications/drug therapy , Diabetes Complications/pathology , Galactitol/metabolism , Humans , Hypoglycemia/drug therapy , Hypoglycemia/pathology , Kinetics , Lens, Crystalline/drug effects , Plant Extracts/chemistry , Rats , Zea mays/chemistry
14.
PLoS One ; 8(4): e61327, 2013.
Article in English | MEDLINE | ID: mdl-23613832

ABSTRACT

Aldose Reductase (AR) is implicated in the development of secondary complications of diabetes, providing an interesting target for therapeutic intervention. Extracts of Rauvolfia serpentina, a medicinal plant endemic to the Himalayan mountain range, have been known to be effective in alleviating diabetes and its complications. In this study, we aim to prospect for novel plant-derived inhibitors from R. serpentina and to understand structural basis of their interactions. An extensive library of R. serpentina molecules was compiled and computationally screened for inhibitory action against AR. The stability of complexes, with docked leads, was verified using molecular dynamics simulations. Two structurally distinct plant-derived leads were identified as inhibitors: indobine and indobinine. Further, using these two leads as templates, 16 more leads were identified through ligand-based screening of their structural analogs, from a small molecules database. Thus, we obtained plant-derived indole alkaloids, and their structural analogs, as potential AR inhibitors from a manually curated dataset of R. serpentina molecules. Indole alkaloids reported herein, as a novel structural class unreported hitherto, may provide better insights for designing potential AR inhibitors with improved efficacy and fewer side effects.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Diabetes Complications/drug therapy , Diabetes Mellitus/drug therapy , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Plant Extracts/therapeutic use , Rauwolfia/chemistry , Aldehyde Reductase/chemistry , Diabetes Complications/enzymology , Diabetes Mellitus/enzymology , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemistry , Humans , Hydrogen Bonding , Hyperglycemia/enzymology , Hyperglycemia/pathology , Molecular Docking Simulation , Oxidative Stress/drug effects , Plant Extracts/pharmacology , ROC Curve , Reproducibility of Results , Structure-Activity Relationship
15.
Basic Res Cardiol ; 108(3): 329, 2013 May.
Article in English | MEDLINE | ID: mdl-23460046

ABSTRACT

Impaired mitochondrial biogenesis causes skeletal muscle damage in diabetes. However, whether and how mitochondrial biogenesis is impaired in the diabetic heart remains largely unknown. Whether adiponectin (APN), a potent cardioprotective molecule, regulates cardiac mitochondrial function has also not been previously investigated. In this study, electron microscopy revealed significant mitochondrial disorders in ob/ob cardiomyocytes, including mitochondrial swelling and cristae disorientation and breakage. Moreover, mitochondrial biogenesis of ob/ob cardiomyocytes is significantly impaired, as evidenced by reduced Ppargc-1a/Nrf-1/Tfam mRNA levels, mitochondrial DNA content, ATP content, citrate synthase activity, complexes I/III/V activity, AMPK phosphorylation, and increased PGC-1α acetylation. Since APN is an upstream activator of AMPK and APN plasma levels are significantly reduced in ob/ob mice, we further tested the hypothesis that reduced APN in ob/ob mice is causatively related to mitochondrial biogenesis impairment. One week of APN treatment of ob/ob mice activated AMPK, reduced PGC-1α acetylation, increased mitochondrial biogenesis, and attenuated mitochondrial disorders. In contrast, knocking out APN inhibited AMPK-PGC-1α signaling and impaired both mitochondrial biogenesis and function. The ob/ob mice exhibited lower survival rates and exacerbated myocardial injury after MI, when compared to controls. APN supplementation improved mitochondrial biogenesis and attenuated MI injury, an effect that was almost completely abrogated by the AMPK inhibitor compound C. In high glucose/high fat treated neonatal rat ventricular myocytes, siRNA-mediated knockdown of PGC-1α blocked gAd-enhanced mitochondrial biogenesis and function and attenuated protection against hypoxia/reoxygenation injury. In conclusion, hypoadiponectinemia impaired AMPK-PGC-1α signaling, resulting in dysfunctional mitochondrial biogenesis that constitutes a novel mechanism for rendering diabetic hearts more vulnerable to enhanced MI injury.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Adiponectin/metabolism , Diabetes Complications/enzymology , Mitochondria, Heart/enzymology , Mitochondrial Turnover , Myocardial Infarction/enzymology , Myocardium/enzymology , Signal Transduction , Trans-Activators/metabolism , Acetylation , Adenosine Triphosphate/metabolism , Adiponectin/deficiency , Adiponectin/genetics , Animals , Animals, Newborn , Cells, Cultured , DNA, Mitochondrial/metabolism , DNA-Binding Proteins/metabolism , Diabetes Complications/genetics , Diabetes Complications/pathology , Diabetes Complications/physiopathology , Diabetes Complications/prevention & control , Disease Models, Animal , Electron Transport Chain Complex Proteins/metabolism , Energy Metabolism , High Mobility Group Proteins/metabolism , Leptin/deficiency , Leptin/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Electron , Mitochondria, Heart/pathology , Mitochondrial Swelling , Myocardial Infarction/genetics , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Myocardial Infarction/prevention & control , Myocardium/pathology , Nuclear Respiratory Factor 1/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , RNA Interference , RNA, Messenger/metabolism , RNA-Binding Proteins/metabolism , Rats , Rats, Sprague-Dawley , Time Factors , Trans-Activators/genetics , Transcription Factors/metabolism , Transfection
16.
J Dermatolog Treat ; 23(5): 345-84, 2012 Oct.
Article in English | MEDLINE | ID: mdl-21756141

ABSTRACT

Advanced glycation Maillard reaction end products (AGEs) are causing the complications of diabetes and skin aging, primarily via adventitious and cross-linking of proteins. Long-lived proteins such as structural collagen are particularly implicated as pathogenic targets of AGE processes. The formation of α-dicarbonyl compounds represents an important step for cross-linking proteins in the glycation or Maillard reaction. The purpose of this study was to investigate the contribution of glycation coupled to the glycation free-radical oxidation reactions as markers of protein damage in the aging of skin tissue proteins and diabetes. To elucidate the mechanism for the cross-linking reaction, we studied the reaction between a three-carbon α-dicarbonyl compound, methylglyoxal, and amino acids using EPR spectroscopy, a spectrophotometric kinetic assay of superoxide anion production at the site of glycation and a chemiluminescence technique. The transglycating activity, inhibition of transition metal ions peroxidative catalysts, resistance to hydrolysis of carnosine mimetic peptide-based compounds with carnosinase and the protective effects of carnosine, carcinine and related compounds against the oxidative damage of proteins and lipid membranes were assessed in a number of biochemical and model systems. A 4-month randomized, double-blind, controlled study was undertaken including 42 subjects where the oral supplement of non-hydrolized carnosine (Can-C Plus® formulation) was tested against placebo for 3 months followed by a 1-month supplement-free period for both groups to assess lasting effects. Assessment of the age-related skin parameters and oral treatment efficacy measurements included objective skin surface evaluation with Visioscan® VC 98 and visual assessment of skin appearance parameters. The results together confirm that a direct one-electron transfer between a Schiff base methylglyoxal dialkylimine (or its protonated form) and methylglyoxal is responsible for the generation of the cross-linked radical cation and the radical counteranion of methylglyoxal. Under aerobic conditions, molecular oxygen can then accept an electron from the methylglyoxal anion to generate the superoxide radical anion causing the propagation of oxidative stress chain reactions in the presence of transition metal ions. Carnosine stabilized from enzymatic hydrolysis, carcinine and leucyl-histidylhydrazide in patented formulations thereof, demonstrate the Schiff bases' transglycating activities concomitant with glycation site specific antioxidant activities and protection of proprietary antioxidant enzymes in the skin during aging and with diabetes lesions. During oral supplementation with stabilized from enzymatic hydrolysis carnosine (Can-C Plus® formulation), the skin parameters investigated showed a continuous and significant improvement in the active group during the 3 months of supplementation as compared to placebo. Visual investigation showed improvement of the overall skin appearance and a reduction of fine lines. No treatment-related side effects were reported. The finding that already-formed AGE cross-links can be pharmacologically severed and attendant pathology thereby reversed by non-hydrolized carnosine or carcinine in patented oral formulations thereof has broad implications for the skin beautification and therapeutics of the complications of diabetes and skin diseases associated with aging.


Subject(s)
Carnosine/analogs & derivatives , Carnosine/therapeutic use , Dermatologic Agents/therapeutic use , Diabetes Complications/drug therapy , Skin Aging/drug effects , Skin Diseases/drug therapy , Adolescent , Adult , Aged , Carnosine/chemistry , Ceruloplasmin/metabolism , Dermatologic Agents/chemistry , Diabetes Complications/enzymology , Diabetes Complications/metabolism , Double-Blind Method , Female , Free Radicals/metabolism , Glycation End Products, Advanced/chemistry , Glycation End Products, Advanced/metabolism , Humans , Lysine/chemistry , Lysine/metabolism , Middle Aged , Oxidative Stress/drug effects , Pyruvaldehyde/chemistry , Pyruvaldehyde/metabolism , Schiff Bases/chemistry , Skin Aging/pathology , Skin Diseases/enzymology , Skin Diseases/metabolism , Young Adult
17.
Phytomedicine ; 18(8-9): 769-75, 2011 Jun 15.
Article in English | MEDLINE | ID: mdl-21242072

ABSTRACT

Crataegus laevigata is a medicinal plant most commonly used for the treatment of heart failure and psychosomatic disorders. Based on previous experimental findings, this double-blind placebo-controlled study was aimed at finding beneficial effects of C. laevigata on biomarkers of coronary heart disease (CHD). The study included 49 diabetic subjects with chronic CHD who were randomly assigned to the treatment for 6 months with either a micronized flower and leaf preparation of C. laevigata (400 mg three times a day) or a matching placebo. Blood cell count, lipid profile, C-reactive protein, neutrophil elastase (NE) and malondialdehyde were analyzed in plasma at baseline, at one month and six months. The main results were that NE decreased in the C. laevigata group compared to the placebo group. In the C. laevigata group, baseline figures (median and interquartile range) were 35.8 (4.5) and in the placebo group 31 (5.9). At the end of the study, values were 33.2 (4.7) ng/ml and 36.7 (2.2) ng/ml, respectively; p<0.0001. C. laevigata, added to statins, decreased LDL cholesterol (LDL-C) (mean±SD) from 105±28.5 mg/dl at baseline to 92.7±25.1 mg/dl at 6 months (p=0.03), and non-HDL cholesterol from 131±37.5 mg/dl to 119.6±33 mg/dl (p<0.001). Differences between groups did not reach statistical significance at 6 months. No significant changes were observed in the rest of parameters. In conclusion, C. laevigata decreased NE and showed a trend to lower LDL-C compared to placebo as add-on-treatment for diabetic subjects with chronic CHD.


Subject(s)
Coronary Disease/drug therapy , Crataegus/chemistry , Diabetes Mellitus, Type 2/drug therapy , Leukocyte Elastase/blood , Plant Extracts/therapeutic use , Aged , C-Reactive Protein/metabolism , Cholesterol, LDL/blood , Coronary Disease/blood , Coronary Disease/enzymology , Diabetes Complications/blood , Diabetes Complications/drug therapy , Diabetes Complications/enzymology , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/enzymology , Double-Blind Method , Flowers/chemistry , Humans , Lipid Peroxidation , Middle Aged , Phytotherapy , Plant Leaves/chemistry
18.
J Diabetes Complications ; 24(3): 199-208, 2010.
Article in English | MEDLINE | ID: mdl-19230716

ABSTRACT

Diabetic cardiomyopathy is associated with high morbidity and mortality of heart failure. Overactivation of the local chymase-Ang II system plays a dominant role in diabetic cardiomyopathy. Astragalus polysaccharide (APS) is used in traditional Chinese medicine to boost immunity. To study the effect of APS on local system of chymase-Ang II in diabetic cardiomyopathy, we investigated APS/normal saline (NS)-administrated streptozotocin-induced diabetic hamsters. After APS/NS administration at a dose of 1 g/kg per day for 10 weeks, hemodynamic parameters, levels of insulin (INS), C-peptide (C-P), glycosylated serum protein (GSP), lipoproteins, myocardial enzymes, and Ang II (plasma and myocardial) were tested; myocardial collagen (type I and III), myocardial ultrastructure, and activities of matrix metalloproteinase (MMPs) were measured; activities and expression of cardiac chymase and ACE were detected by using quantitative real-time RT-PCR and RIA; protein expression of cardiac phosphoric extracellular signal-regulated kinase 1/2 (p-ERK1/2) was measured by Western blot. AP-administrated diabetic hamsters had lower levels of GSP, lipoproteins, myocardial enzymes, myocardial Ang II, expression of collagen I and I/ III, activities of pro-MMP-2 and MMP-2, activities and expression of chymase, and expression of p-ERK1/2 than NS-administrated diabetic hamsters and could better protect the myocardial ultrastructure. There was no difference in hemodynamic parameters between two groups. These results indicate that APS could inhibit diabetic cardiomyopathy in hamsters depending on the suppression of the local cardiac chymase-Ang II system.


Subject(s)
Astragalus propinquus , Cardiomyopathies/drug therapy , Chymases/drug effects , Diabetes Complications/drug therapy , Phytotherapy , Plant Preparations/therapeutic use , Polysaccharides/therapeutic use , Angiotensin II/analysis , Animals , Blood Glucose/analysis , Blood Proteins/analysis , Cardiomyopathies/enzymology , Collagen/analysis , Cricetinae , Diabetes Complications/enzymology , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/enzymology , Extracellular Signal-Regulated MAP Kinases/analysis , Glycoproteins/analysis , Lipoproteins/analysis , Male , Matrix Metalloproteinase 2/analysis , Glycated Serum Proteins
19.
Zhong Yao Cai ; 32(8): 1259-61, 2009 Aug.
Article in Chinese | MEDLINE | ID: mdl-19960952

ABSTRACT

OBJECTIVE: To observe the activities of baicalin, berberine and Astragalus polysaccharides and their combinative effects on aldose reductase (AR) by a screening model of aldose reductase inhibitor (ARI) in vitro. METHODS: The inhibition of AR by baicalin, berberine and Astragalus polysaccharides and positive drug (Epalrestat) in different concentrations were evaluated, and their combinative effects were studied according to orthogonal t design. RESULTS: Baicalin and berberine had remarkable inhibitory effects on AR, the inhibitory rates were (88.4 +/- 7.4)% and (69.0 +/- 9.4)% at the concentration of 300 microg/mL. However, the combinative effect of the inhibition on AR by the two compounds was antagonistic action. Astragalus polysaccharides had no activity of inhibition on AR. CONCLUSION: Baicalin and berberine are the potential AR inhibitors as they can inhibit the activity of AR in vitro.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Aldehyde Reductase/pharmacology , Berberine/pharmacology , Flavonoids/pharmacology , Plants, Medicinal/chemistry , Astragalus propinquus/chemistry , Berberine/administration & dosage , Berberine/chemistry , Diabetes Complications/enzymology , Diabetes Complications/prevention & control , Enzyme Inhibitors/pharmacology , Flavonoids/administration & dosage , Flavonoids/chemistry , Polysaccharides/administration & dosage , Polysaccharides/chemistry , Polysaccharides/pharmacology , Structure-Activity Relationship
20.
Lasers Med Sci ; 24(4): 591-6, 2009 Jul.
Article in English | MEDLINE | ID: mdl-18982402

ABSTRACT

The aim of this study was to evaluate the effect of laser irradiation (LI) on enzymatic activities of amylase, catalase and peroxidase in the parotid glands (PG) of diabetic and non-diabetic rats. Ninety-six female rats were divided into eight groups: D0; D5; D10; D20 and C0; C5; C10; C20, respectively. Diabetes was induced by administration of streptozotocin and confirmed later by the glycemia results. Twenty-nine (29) days after the induction, the PGs of groups D5 and C5; D10 and C10; D20 and C20, were irradiated with 5 J/cm(2), 10 J/cm(2) and 20 J/cm(2) of laser diode (660 nm/100 mW) respectively. On the following day, the rats were euthanized and the enzymatic activity in the PGs was measured. Diabetic rats that had not been irradiated (group D0) showed higher catalase activity (P < 0.05) than those in group C0 (0.14 +/- 0.02 U/mg protein and 0.10 +/- 0.03 U/mg protein, respectively). However, laser irradiation of 5 J/cm(2) and 20 J/cm(2) decreased the catalase activity of the diabetic groups (D5 and D20) to non-diabetic values (P > 0.05). Based on the results of this study, LI decreased catalase activity in the PGs of diabetic rats.


Subject(s)
Diabetes Mellitus, Experimental/enzymology , Diabetes Mellitus, Experimental/radiotherapy , Lasers, Semiconductor/therapeutic use , Low-Level Light Therapy , Parotid Gland/enzymology , Parotid Gland/radiation effects , Amylases/metabolism , Animals , Catalase/metabolism , Diabetes Complications/enzymology , Diabetes Complications/etiology , Female , Humans , Peroxidase/metabolism , Rats , Rats, Wistar , Xerostomia/enzymology , Xerostomia/etiology , Xerostomia/radiotherapy
SELECTION OF CITATIONS
SEARCH DETAIL